Patents by Inventor Marc Allan Eichmeyer

Marc Allan Eichmeyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160193320
    Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
    Type: Application
    Filed: March 21, 2016
    Publication date: July 7, 2016
    Inventors: Michael B. Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
  • Publication number: 20150297707
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein.
    Type: Application
    Filed: June 30, 2015
    Publication date: October 22, 2015
    Inventors: Michael B. Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel
  • Publication number: 20150297708
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine.
    Type: Application
    Filed: June 30, 2015
    Publication date: October 22, 2015
    Inventors: Michael B. Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel
  • Publication number: 20150190498
    Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
    Type: Application
    Filed: March 18, 2015
    Publication date: July 9, 2015
    Inventors: Michael B. Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
  • Patent number: 9011872
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: April 21, 2015
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
  • Publication number: 20110059126
    Abstract: The present invention provides methods of reducing the vircidal activity of a composition comprising a PCV-2 antigen as well as antigenic preparations and immunogenic compositions comprising a PCV-2 antigen, wherein the virucidal activity has been reduced. In addition, the present invention also relates to a method of increasing the immunogenicity of an immunogenic composition comprising a PCV-2 antigen as well as immunogenic composition with an increased immunogenicity.
    Type: Application
    Filed: September 2, 2010
    Publication date: March 10, 2011
    Applicant: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Caroline Ann Kohler, Guosong Zhao, Ali Khazraeinazmpour, Bernd Colin Eichenmueller, Marc Allan Eichmeyer, Gregory Haiwick, Merrill Lynn Schaeffer